Bu sayfada
NKTR Nektar Therapeutics - Common Stock
NASDAQ · Pharmaceuticals · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 14, 2026
$43,58
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$33,4052 haftanın en düşüğü
$109,0052 haftanın en yükseği
Piyasa Değeri (MRQ)
$888M
P/E (TTM)
-4.5
Hisse Başına Kâr (TTM)
$-9.59
Gelir (TTM)
$55M
rozetleriniz
52 Haftlık Aralık
$33–$109
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$141
P/E
-4.5
ROE
-35.8%
Net Kâr Marjı
-287.8%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
NKTR Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$43.58
Piyasa Değeri (MRQ)
$888M
P/E (TTM)
-4.5
Hisse Başına Kâr (TTM)
$-9.59
Gelir (TTM)
$55M
ROE (TTM)
-35.8%
52 Haftlık Aralık
$33–$109
NKTR Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
Hisse bölünmeleri
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 09 Haziran 2025 | 1-for-15 | Ters |
| 23 Ağustos 2000 | 2-for-1 | İleri |
Nektar Therapeutics - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.
Background
The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.
In 2013, the company was assigned a patent which was developed by the company and other four co-inventors. The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide. As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.
As of December 2024, at a stock price-per-share of roughly $1, the market cap is roughly $171 million. Nektar underwent periods of downsizing after unsuccessful partnerships were ended with Eli Lilly in 2023 and Bristol Myers Squibb in 2022, resulting in layoffs of most company employees.
Pipeline
Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016. The European Medicines Agency refused a marketing authorisation in 2017.
Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine, Phase I results were announced in November 2016. It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.
In 2023 Nektar's partnership with Eli Lilly in development of "rezpeg" was ended. Eli Lilly claimed the drug lacked suitable efficacy, while Nektar responded that Eli Lilly had botched the analysis.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
sektörHealthcare
endüstriPharmaceuticals
çalışanlar63
ülkeUS
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$55M2016-12-31 → 2025-12-31
Hisse Başına Kâr$-9.732016-12-31 → 2025-12-31
Serbest Nakit Akışı$-209M2016-12-31 → 2025-12-31
Net kar marjı-287.8%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | NKTR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | -4.55Y ort. ≈-20.0 | ≈-20.0 | · | · | |
| F/S (TTM) | 16.35Y ort. ≈99.6 | ≈99.6 | 4.5 | Aşırı değerli | |
| F/D (MRQ) | 1.05Y ort. ≈27.5 | ≈27.5 | 7.2 | Düşük değerli | |
| Fiyat / Serbest Nakit Akışı (TTM) | -3.85Y ort. ≈-27.1 | ≈-27.1 | · | · | |
| Fiyat / Nakit Akışı (TTM) | -3.85Y ort. ≈-27.9 | ≈-27.9 | · | · | |
| Price / Tangible Book (Fiyat / Maddi Defter Değeri) | 14.35Y ort. ≈29.8 | ≈29.8 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | NKTR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | -257.8%5Y ort. ≈-299.9% | ≈-299.9% | -26.5% | Zayıf | |
| EBITDA Margin (FAVÖK Marjı) | -253.7%5Y ort. ≈-292.3% | ≈-292.3% | -18.9% | Zayıf | |
| Vergi Öncesi Kar Marjı (TTM) | -296.5%5Y ort. ≈-327.0% | ≈-327.0% | -14.3% | Zayıf | |
| Net Kâr Marjı (TTM) | -287.8%5Y ort. ≈-327.6% | ≈-327.6% | -10.7% | Zayıf | |
| ROA (TTM) | -24.1%5Y ort. ≈-43.9% | ≈-43.9% | -12.8% | Zayıf | |
| ROE (TTM) | -35.8%5Y ort. ≈-214.5% | ≈-214.5% | -21.0% | Zayıf | |
| ROIC | -155.8%5Y ort. ≈-139.8% | ≈-139.8% | -22.1% | Zayıf |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | NKTR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Cari Oran (MRQ) | 10.45Y ort. ≈6.6 | ≈6.6 | 5.5 | Güçlü likidite | |
| Quick Ratio (Cari Oran) | 0.35Y ort. ≈0.7 | ≈0.7 | 1.5 | Düşük likidite |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | NKTR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | -43.9%5Y ort. ≈-16.0% | ≈-16.0% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | -15.7%5Y ort. ≈-11.0% | ≈-11.0% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | -18.4% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | NKTR | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.25Y ort. ≈0.2 | ≈0.2 | 0.5 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$876.7K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
8.3%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 13, 2026 | $-1.23 | $-2.02 | 39.2% |
| 31 Mart 2026 | May 7, 2026 | $-1.82 | $-1.63 | -11.9% |
| 31 Aralık 2025 | $-1.78 | $-2.52 | 29.5% | |
| 30 Eylül 2025 | $-1.87 | $-2.74 | 31.7% | |
| 30 Haziran 2025 | $-2.95 | $-3.10 | 4.7% | |
| 31 Mart 2025 | $-3.60 | $-2.51 | -43.2% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Cost of Revenue | $0 | $31M | $34M | $22M | $25M | $19M | $21M | $24M | $31M | $30M | $34M | $29M | |
| R&D Expense | $117M | $121M | $114M | $218M | $400M | $409M | $435M | $400M | $268M | $204M | $183M | $148M | |
| SG&A Expense | $69M | $77M | $77M | $92M | $123M | $105M | $99M | $81M | $52M | $44M | $43M | $41M | |
| Operating Expenses | $195M | $204M | $354M | $468M | $548M | $578M | $555M | $505M | $367M | $278M | $260M | $217M | |
| Operating Income | $-140M | $-105M | $-264M | $-376M | $-446M | $-425M | $-440M | $688M | $-60M | $-113M | $-29M | $-16M | |
| Interest Expense | · | · | · | $0 | $0 | $7M | $21M | $22M | $22M | $22M | $18M | $18M | |
| Interest Income | $10M | $14M | $19M | $7M | $3M | · | · | · | · | · | · | · | |
| Other Non-op | $361.0K | $-390.0K | $-6M | $-116.0K | $-162.0K | $18M | $46M | $38M | $5M | $2M | $2M | $814.0K | |
| Pretax Income | $-164M | $-119M | $-276M | $-365M | $-523M | $-444M | $-440M | $683M | $-96M | $-153M | $-81M | $-54M | |
| Income Tax | $-138.0K | $-239.0K | $-200.0K | $3M | $557.0K | $493.0K | $613.0K | $1M | $616.0K | $876.0K | $506.0K | $-512.0K | |
| Net Income | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| EPS (Basic) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $4.02 | $-0.62 | $-1.10 | · | · | |
| EPS (Diluted) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | · | · | |
| Shares (Basic) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 169,600,000 | 155,953,000 | 139,596,000 | · | · | |
| Shares (Diluted) | 16,870,930 | 13,710,775 | 190,001,000 | 187,138,000 | 183,298,000 | 178,581,000 | 174,993,000 | 180,119,000 | 155,953,000 | 139,596,000 | · | · | |
| EBITDA | $-140M | $-101M | $-257M | $-364M | $-433M | $-413M | $-429M | $697M | $-47M | $-113M | $-29M | · |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15M | $44M | $35M | $88M | $25M | $199M | $96M | $195M | $5M | $60M | $56M | $12M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $291M | $329M | $253M | $225M | |
| Receivables | · | $0 | $1M | $6M | $22M | $39M | $37M | $43M | $5M | $16M | $20M | $4M | |
| Inventory | $0 | $0 | $16M | $19M | $16M | $15M | $13M | $11M | $11M | $11M | $11M | $13M | |
| Other Current Assets | $21M | $6M | $10M | $16M | $23M | $22M | $15M | $21M | $8M | $10M | $10M | $9M | |
| Current Assets | $266M | $261M | $331M | $546M | $796M | $1.14B | $1.42B | $1.44B | $327M | $426M | $350M | $288M | |
| PP&E (Net) | $2M | $3M | $19M | $32M | $61M | $60M | $66M | $49M | $47M | $66M | $71M | $70M | |
| Accum. Depreciation | · | $16M | $87M | $125M | $148M | $138M | $128M | $121M | $115M | $111M | $103M | $94M | |
| Goodwill | · | · | $0 | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | $77M | |
| Other Non-current Assets | $14M | $5M | $5M | $2M | $3M | $1M | $344.0K | $4M | $994.0K | $817.0K | $754.0K | $7M | |
| Total Assets | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Accounts Payable | $11M | $12M | $10M | $13M | $10M | $22M | $19M | $6M | $5M | $3M | $2M | $3M | |
| Accrued Liabilities | $22M | $30M | $22M | $37M | · | · | · | · | · | · | · | $6M | |
| Current Liabilities | $54M | $61M | $51M | $68M | $85M | $116M | $354M | $82M | $56M | $72M | $61M | $64M | |
| Capital Leases | $65M | $83M | $99M | $113M | $126M | $136M | $143M | $0 | · | $2M | $1M | $4M | |
| Other Non-current Liabilities | $9M | $7M | $5M | $8M | $4M | $9M | $768.0K | $10M | $6M | $7M | $10M | $15M | |
| Total Liabilities | $191M | $243M | $267M | $344M | $438M | $461M | $572M | $433M | $421M | $481M | $492M | $405M | |
| Common Stock | $2.0K | $1.0K | $19.0K | $19.0K | $19.0K | $18.0K | $17.0K | $17.0K | $15.0K | $15.0K | $13.0K | $13.0K | |
| Retained Earnings | $-3.76B | $-3.60B | $-3.48B | $-3.20B | $-2.83B | $-2.31B | $-1.86B | $-1.42B | $-2.12B | $-2.02B | $-1.87B | $-1.79B | |
| Treasury Stock | · | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $17.0K | $61.0K | $80.0K | $-7M | $-4M | $-2M | $-1M | $-6M | $-2M | $-2M | $-2M | $-2M | |
| Stockholders' Equity | $90M | $61M | $131M | $367M | $680M | $1.08B | $1.41B | $1.72B | $88M | $88M | $6M | $36M | |
| Liabilities + Equity | $280M | $304M | $398M | $711M | $1.12B | $1.54B | $1.98B | $2.15B | $509M | $569M | $499M | $442M | |
| Shares Outstanding | 20,378,832 | 12,385,001 | 12,757,984 | 188,560,000 | 185,468,000 | 180,091,000 | 176,505,000 | 173,530,000 | 159,524,000 | 153,212,000 | 135,289,000 | 131,216,000 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $4M | $7M | $12M | $13M | $12M | $11M | $9M | $13M | $13M | $11M | $13M | |
| Stock-based Comp | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Deferred Tax | $64.0K | $-10.0K | $-140.0K | $3M | $-102.0K | $-36.0K | $-21.0K | $93.0K | $35.0K | $-115.0K | $-22.0K | $-31.0K | |
| Other Non-cash | · | $-61M | $77M | $49M | $98M | $119M | $101M | $28M | $4M | · | · | · | |
| Operating Cash Flow | $-209M | $-176M | $-193M | $-304M | $-413M | $-313M | $-329M | $718M | $-80M | $-117M | $-73M | $-142M | |
| CapEx | $171.0K | $1M | $865.0K | $6M | $15M | $7M | $26M | $14M | $10M | $6M | $11M | $10M | |
| Investing Cash Flow | $-1M | $143M | $140M | $366M | $203M | $496M | $207M | $-1.38B | $-29M | $-82M | · | · | |
| Stock Repurchased | $0 | $3M | $0 | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $0 | $-3M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $181M | $42M | $30.0K | $2M | $36M | $-80M | $23M | $852M | $54M | $204M | · | · | |
| Net Change in Cash | $-29M | $9M | $-53M | $63M | $-174M | $103M | $-99M | $190M | $-55M | $4M | $43M | $-27M | |
| Taxes Paid | $-195.0K | $76.0K | $3M | $272.0K | $325.0K | $539.0K | $555.0K | $618.0K | $556.0K | $757.0K | $860.0K | $964.0K | |
| Free Cash Flow | $-209M | $-177M | $-193M | $-310M | $-428M | $-321M | $-355M | $704M | $-90M | $-123M | $-84M | · | |
| Levered FCF | · | · | · | $-310M | $-428M | $-327M | $-376M | $682M | $-112M | $-146M | $-103M | · |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% | -278.0% | -383.9% | 57.6% | -19.4% | -68.2% | -12.7% | · | |
| Net Margin | -297.1% | -120.9% | -306.3% | -400.0% | -514.0% | -290.6% | -384.5% | 57.1% | -31.4% | -92.8% | -35.2% | · | |
| Pretax Margin | -297.3% | -121.1% | -306.5% | -396.5% | -513.5% | -290.3% | -383.9% | 57.2% | -31.2% | -92.3% | -35.0% | · | |
| EBITDA Margin | -253.7% | -102.7% | -284.8% | -395.4% | -425.0% | -269.8% | -374.3% | 58.4% | -15.3% | -68.2% | -12.7% | · | |
| ROA | -56.2% | -33.9% | -49.8% | -40.3% | -39.5% | -25.3% | -21.3% | 51.2% | -17.9% | -28.8% | -17.2% | · | |
| ROE | -500.1% | -217.0% | -190.2% | -94.5% | -70.7% | -39.5% | -30.4% | 38.9% | -109.9% | -324.7% | -379.7% | · | |
| ROIC | -155.8% | -172.9% | -201.2% | -103.5% | -65.7% | -39.5% | -31.4% | 40.0% | -68.3% | -128.8% | -459.7% | · |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 | 9.8 | 4.0 | 17.5 | 5.8 | 5.9 | 5.7 | · | |
| Quick Ratio | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 | 2.1 | 0.4 | 2.9 | 5.4 | 5.6 | 5.4 | · | |
| Interest Coverage | · | · | · | · | · | -62.1 | -20.6 | 31.9 | -2.7 | -5.0 | -1.6 | · |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.9 | 0.6 | 0.3 | 0.5 | · | |
| Inventory Turnover | · | 3.8 | 1.9 | 1.2 | 1.6 | 1.4 | 1.8 | 2.2 | 2.8 | 2.7 | 2.8 | · | |
| Receivables Turnover | · | 163.4 | 25.1 | 6.5 | 3.3 | 4.0 | 2.9 | 49.5 | 29.7 | 9.3 | 19.6 | · |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $4.41 | $0.33 | $0.68 | $1.94 | $3.66 | $5.98 | $7.96 | $9.90 | $0.55 | $0.58 | $0.05 | · | |
| Revenue / Share | $3.27 | $0.48 | $0.47 | $0.49 | $0.56 | $0.86 | $0.66 | $6.63 | · | · | · | · | |
| Cash Flow / Share | $-12.36 | $-0.85 | $-1.01 | $-1.62 | $-2.25 | $-1.75 | $-1.88 | $3.99 | · | · | · | · | |
| Cash / Share | $0.74 | $0.24 | $0.18 | $0.47 | $0.14 | $1.10 | $0.55 | $1.12 | $0.03 | $0.39 | $0.41 | · | |
| EPS (TTM) | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 | $-2.49 | $-2.52 | $3.78 | $-0.62 | $-1.10 | $-0.61 | $-0.45 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -43.9% | 9.2% | -2.1% | -9.7% | -33.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -15.7% | -1.1% | -16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -18.4% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $98M | $90M | $92M | $102M | $153M | $115M | $1.19B | $308M | $165M | $231M | $201M | |
| Net Income TTM | $-164M | $-119M | $-276M | $-368M | $-524M | $-444M | $-441M | $681M | $-97M | $-154M | $-81M | $-54M | |
| Market Cap | $862M | $2.59B | $1.61B | $6.39B | $37.59B | $45.92B | $57.16B | $85.56B | $142.90B | $28.20B | $34.19B | · | |
| P/E | -4.3 | -1.6 | -5.8 | -17.2 | -70.9 | -102.4 | -128.5 | 130.4 | -1444.8 | -167.3 | -414.3 | -516.7 | |
| P/S | 15.6 | 26.3 | 17.8 | 69.4 | 368.8 | 300.3 | 498.7 | 71.7 | 464.4 | 170.5 | 148.2 | · | |
| P/B | 9.6 | 42.7 | 12.3 | 17.4 | 55.3 | 42.6 | 40.7 | 49.8 | 1627.1 | 320.0 | 5318.8 | · | |
| P / Tangible Book | 9.6 | 42.7 | 12.3 | 22.0 | 62.3 | 45.9 | · | · | · | · | · | · | |
| P / Cash Flow | -4.1 | -14.7 | -8.3 | -21.0 | -91.1 | -146.6 | -173.9 | 119.1 | -1777.1 | -241.0 | -467.9 | · | |
| P / FCF | -4.1 | -14.6 | -8.3 | -20.6 | -87.9 | -143.3 | -161.0 | 121.5 | -1586.2 | -228.5 | -405.7 | · | |
| Earnings Yield | -23.0% | -62.2% | -17.3% | -5.8% | -1.4% | -0.98% | -0.78% | 0.77% | -0.07% | -0.60% | -0.24% | -0.19% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10M | $11M | $22M | $12M | $11M | $10M | $29M | $24M | $23M | $22M | $24M | $24M | $20M | $22M | $22M | $24M | |
| Cost of Revenue | · | · | $0 | $0 | $0 | $0 | $8M | $4M | $10M | $9M | $7M | $12M | $7M | $7M | $6M | $5M | |
| R&D Expense | $39M | $36M | $30M | $27M | $30M | $30M | $29M | $35M | $30M | $27M | $30M | $24M | $30M | $30M | $35M | $34M | |
| SG&A Expense | $13M | $13M | $11M | $16M | $17M | $24M | $17M | $19M | $21M | $20M | $17M | $21M | $18M | $21M | $22M | $23M | |
| Operating Expenses | $52M | $50M | $49M | $43M | $47M | $55M | $15M | $58M | $73M | $57M | $57M | $69M | $71M | $156M | $74M | $78M | |
| Operating Income | $-42M | $-39M | $-28M | $-32M | $-36M | $-45M | $14M | $-34M | $-50M | $-35M | $-34M | $-45M | $-51M | $-135M | $-52M | $-54M | |
| Interest Income | $9M | $4M | $3M | $3M | $2M | $3M | $3M | $3M | $4M | $4M | $5M | $5M | $5M | $4M | · | · | |
| Other Non-op | $-100.0K | $-336.0K | $-44.0K | $-121.0K | $260.0K | $266.0K | $-135.0K | $-120.0K | $-36.0K | $-99.0K | $-6M | $-335.0K | $736.0K | $-301.0K | $-4M | $2M | |
| Pretax Income | $-40M | $-43M | $-43M | $-35M | $-39M | $-46M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-57M | $-59M | |
| Income Tax | $2.0K | $64.0K | $31.0K | $-33.0K | $-188.0K | $52.0K | $-259.0K | $9.0K | $46.0K | $-35.0K | $-29.0K | $-61.0K | $-47.0K | $-63.0K | $3M | $-155.0K | |
| Net Income | $-41M | $-45M | $-36M | $-36M | $-42M | $-51M | $7M | $-37M | $-52M | $-37M | $-42M | $-46M | $-51M | $-137M | $-60M | $-59M | |
| EPS (Basic) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| EPS (Diluted) | $-1.23 | $-1.82 | $-4.67 | $-1.87 | $-2.95 | $-3.62 | $-2.07 | $-2.66 | $-3.76 | $-0.19 | $-0.21 | $-0.24 | $-0.27 | $-0.73 | $-0.32 | $-0.31 | |
| Shares (Basic) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| Shares (Diluted) | 33,054,865 | 24,736,066 | · | 18,946,559 | 14,087,307 | 14,063,402 | · | 13,949,851 | 13,921,378 | 194,746,000 | · | 190,406,000 | 189,656,000 | 188,875,000 | · | 187,641,000 | |
| EBITDA | $-42M | $-39M | · | $-32M | $-36M | $-45M | · | $-34M | $-50M | $-35M | · | $-45M | $-51M | $-135M | · | $-54M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $39M | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M | $49M | $35M | $65M | $51M | $77M | $88M | $106M | |
| Receivables | · | · | · | · | · | · | · | $0 | $1M | $4M | $1M | $2M | $1M | $3M | $6M | $12M | |
| Inventory | · | · | $0 | · | · | · | $0 | $0 | $14M | $16M | $16M | $15M | $21M | $20M | $19M | $19M | |
| Other Current Assets | $55M | $20M | $21M | $11M | $11M | $11M | $6M | $9M | $8M | $11M | $10M | $9M | $10M | $11M | $16M | $23M | |
| Current Assets | $739M | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M | $320M | $331M | $399M | $441M | $491M | $546M | $599M | |
| PP&E (Net) | · | · | $2M | $3M | $3M | $3M | $3M | $4M | $15M | $17M | $19M | $20M | $23M | $27M | $32M | $37M | |
| Accum. Depreciation | · | · | · | · | · | · | · | $16M | $88M | · | $87M | $88M | $108M | $111M | $125M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $77M | $77M | |
| Other Non-current Assets | $17M | $11M | $6M | $5M | $5M | $5M | $5M | $5M | $4M | $5M | $5M | $5M | $2M | $1M | $2M | $2M | |
| Total Assets | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Accounts Payable | $25M | $10M | $11M | $16M | $14M | $18M | $12M | $9M | $6M | $9M | $10M | $3M | $3M | $4M | $13M | $5M | |
| Accrued Liabilities | $23M | $25M | $22M | $29M | $35M | $31M | $30M | $32M | $30M | $24M | $22M | $30M | $29M | $37M | $37M | · | |
| Current Liabilities | $71M | $58M | $54M | $66M | $71M | $71M | $61M | $68M | $57M | $52M | $51M | $52M | $51M | $60M | $68M | $84M | |
| Capital Leases | $56M | $61M | $65M | $70M | $74M | $78M | $83M | $87M | $91M | $95M | $99M | $102M | $106M | $109M | $113M | $116M | |
| Other Non-current Liabilities | $8M | $8M | $9M | $5M | $6M | $7M | $7M | $7M | $8M | $4M | $5M | $5M | $5M | $6M | $8M | $3M | |
| Total Liabilities | $192M | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M | $269M | $267M | $283M | $297M | $321M | $344M | $369M | |
| Common Stock | $3.0K | $3.0K | $2.0K | $2.0K | $1.0K | $19.0K | $1.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | $19.0K | |
| Retained Earnings | $-3.85B | $-3.81B | $-3.76B | $-3.72B | $-3.69B | $-3.65B | $-3.60B | $-3.60B | $-3.57B | $-3.51B | $-3.48B | $-3.44B | $-3.39B | $-3.34B | $-3.20B | $-3.14B | |
| Treasury Stock | · | · | · | $0 | $3M | $3M | $3M | $3M | $3M | $3M | · | · | · | · | · | · | |
| AOCI | $-2M | $-1M | $17.0K | $56.0K | $-14.0K | $39.0K | $61.0K | $355.0K | $-494.0K | $-403.0K | $80.0K | $-6M | $-6M | $-6M | $-7M | $-8M | |
| Stockholders' Equity | $903M | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M | $127M | $131M | $159M | $197M | $241M | $367M | $412M | |
| Liabilities + Equity | $1.10B | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M | $396M | $398M | $442M | $494M | $562M | $711M | $781M | |
| Shares Outstanding | 20,378,832 | 20,378,832 | 20,378,832 | 19,652,513 | 12,457,252 | 186,103,000 | 12,385,001 | 184,458,000 | 184,061,000 | 183,624,000 | 191,384,000 | 190,771,000 | 190,119,000 | 189,235,000 | 188,560,000 | 187,954,000 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $156.0K | $151.0K | $190.0K | $196.0K | $214.0K | $426.0K | $332.0K | $993.0K | $1M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | |
| Deferred Tax | · | · | · | · | · | · | $2.0K | $-31.0K | $57.0K | $-38.0K | $2M | $-15.0K | $-27.0K | $-2M | $3M | $0 | |
| Restructuring | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $17M | |
| Operating Cash Flow | $-76M | $-44M | $-65M | $-49M | $-46M | $-49M | $-46M | $-44M | $-38M | $-48M | $-47M | $-42M | $-52M | $-52M | $-58M | $-83M | |
| CapEx | $94.0K | $18.0K | $18.0K | $114.0K | $37.0K | $2.0K | $459.0K | $666.0K | $186.0K | $157.0K | $237.0K | $33.0K | $162.0K | $433.0K | $512.0K | $181.0K | |
| Investing Cash Flow | $-399M | $-351M | $372.0K | $-95M | $50M | $44M | $60M | $46M | $17M | $19M | $17M | $56M | $25M | $41M | $40M | $111M | |
| Stock Repurchased | · | · | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $0 | · | · | · | $-3M | · | · | · | · | · | · | |
| Financing Cash Flow | $365M | $530M | $39M | $142M | $211.0K | $7.0K | $83.0K | $13.0K | $19.0K | $42M | $12.0K | $0 | $18.0K | $0 | $103.0K | $0 | |
| Net Change in Cash | $-110M | $134M | $-26M | $-2M | $4M | $-5M | $14M | $2M | $-21M | $13M | $-30M | $14M | $-26M | $-11M | $-18M | $28M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | $272.0K | $-85.0K | |
| Free Cash Flow | · | $-44M | · | · | · | $-49M | · | · | · | $-48M | · | · | · | $-52M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| Net Margin | -401.0% | -413.4% | · | -301.3% | -372.2% | -486.4% | · | -153.6% | -222.9% | -170.1% | · | -189.8% | -249.4% | -634.5% | · | -249.9% | |
| Pretax Margin | -397.8% | -396.7% | · | -297.0% | -352.5% | -443.3% | · | -153.6% | -222.7% | -170.2% | · | -190.1% | -249.6% | -634.8% | · | -250.6% | |
| EBITDA Margin | -417.9% | -359.6% | · | -268.6% | -324.2% | -425.8% | · | -142.4% | -211.9% | -163.7% | · | -185.8% | -246.8% | -623.8% | · | -229.9% | |
| ROA | -6.2% | -8.8% | · | -11.7% | -15.1% | -15.6% | · | -9.9% | -12.5% | -7.7% | · | -7.5% | -7.5% | -17.3% | · | -5.7% | |
| ROE | -9.2% | -15.2% | · | -53.0% | -150.0% | -72.5% | · | -35.6% | -37.9% | -20.0% | · | -16.0% | -15.6% | -32.3% | · | -9.7% | |
| ROIC | -4.7% | -6.8% | · | -37.2% | 148.9% | -324.5% | · | -70.3% | -62.5% | -27.9% | · | -28.1% | -25.7% | -55.9% | · | -13.1% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.4 | 10.2 | · | 4.2 | 2.6 | 3.2 | · | 4.2 | 5.1 | 6.1 | · | 7.7 | 8.7 | 8.2 | · | 7.1 | |
| Quick Ratio | 0.6 | 2.6 | · | 0.6 | 0.6 | 0.5 | · | 0.4 | 0.5 | 1.0 | · | 1.3 | 1.0 | 1.3 | · | 1.4 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | · | · | · | · | · | · | · | 0.6 | 0.6 | 0.5 | · | 0.7 | 0.4 | 0.4 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | 21.9 | 18.6 | 6.5 | · | 3.5 | 3.6 | 1.3 | · | 1.2 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $44.32 | $28.28 | · | $4.33 | $-1.94 | $0.07 | · | $0.27 | $0.43 | $0.69 | · | $0.84 | $1.04 | $1.27 | · | $2.19 | |
| Revenue / Share | $0.31 | $0.44 | · | $0.62 | $0.79 | $0.05 | · | $0.12 | $0.11 | $0.11 | · | $0.13 | $0.11 | $0.11 | · | $0.13 | |
| Cash Flow / Share | · | $-1.79 | · | · | · | $-0.23 | · | · | · | $-0.25 | · | · | · | $-0.27 | · | · | |
| Cash / Share | $1.93 | $7.34 | · | $2.09 | $3.45 | $0.21 | · | $0.16 | $0.15 | $0.26 | · | $0.34 | $0.27 | $0.41 | · | $0.56 | |
| EPS (TTM) | $-9.59 | $-11.31 | · | $-10.51 | $-11.30 | $-12.11 | · | $-6.82 | $-4.40 | $-0.91 | · | $-1.56 | $-1.63 | $-2.21 | · | $-2.44 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $55M | $56M | · | $63M | $75M | $87M | · | $93M | $93M | $90M | · | $88M | $88M | $89M | · | $95M | |
| Net Income TTM | $-157M | $-158M | · | $-121M | $-122M | $-133M | · | $-168M | $-177M | $-176M | · | $-294M | $-307M | $-415M | · | $-454M | |
| Market Cap | $1.42B | $1.47B | · | $1.12B | $322M | $1.90B | · | $3.60B | $3.42B | $2.56B | · | $1.72B | $1.65B | $1.99B | · | $9.02B | |
| P/E | -7.3 | -6.4 | · | -5.4 | -2.3 | -0.8 | · | -2.9 | -4.2 | -15.3 | · | -5.8 | -5.3 | -4.8 | · | -19.7 | |
| P/S | 26.1 | 26.4 | · | 17.9 | 4.3 | 21.8 | · | 38.6 | 36.8 | 28.4 | · | 19.5 | 18.9 | 22.4 | · | 94.9 | |
| P/B | 1.6 | 2.5 | · | 13.1 | -13.3 | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 21.9 | |
| P / Tangible Book | 1.6 | 2.5 | · | 13.1 | · | 138.2 | · | 73.6 | 43.0 | 20.2 | · | 10.8 | 8.4 | 8.2 | · | 26.9 | |
| P / Cash Flow | · | -33.1 | · | · | · | -38.7 | · | · | · | -53.5 | · | · | · | -38.3 | · | · | |
| Earnings Yield | -13.7% | -15.7% | · | -18.5% | -43.7% | -118.7% | · | -35.0% | -23.7% | -6.5% | · | -17.3% | -18.7% | -21.1% | · | -5.1% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $55M | $98M | $90M | $92M | $102M |
| Faaliyet Kâr Marjı % | -253.7% | -106.9% | -292.6% | -408.6% | -437.8% |
| Net Gelir | $-164M | $-119M | $-276M | $-368M | $-524M |
| Seyreltilmiş Hisse Başı Kâr | $-9.73 | $-8.68 | $-1.45 | $-1.97 | $-2.86 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Cari Oran | 5.0 | 4.3 | 6.5 | 8.0 | 9.3 |
| Cari Oran | 0.3 | 0.7 | 0.7 | 1.4 | 0.6 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-209M | $-177M | $-193M | $-310M | $-428M |
Kurumsal Sahipler (13F) 267 dosya · $2.7B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
267
Tutulan Değer
$2.7B
Yeni pozisyonlar
78
Çıkan pozisyonlar
42
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 78 (+2 önceki Ç'ye göre) | 42 (+11 önceki Ç'ye göre) | 105 (+27 önceki Ç'ye göre) | 44 (-6 önceki Ç'ye göre) | +10.6M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| FMR LLC | $353.791.520 | 5.067.920 | 13,17% | Hisse senetleri |
| Two Seas Capital LP | $215.868.856 | 3.092.234 | 8,04% | Hisse senetleri |
| BlackRock, Inc. | $205.370.620 | 2.941.851 | 7,64% | Hisse senetleri |
| BVF INC/IL | $166.920.946 | 2.391.075 | 6,21% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $104.495.029 | 1.496.849 | 3,89% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $83.911.899 | 1.202.004 | 3,12% | Hisse senetleri |
| Vestal Point Capital, LP | $69.810.000 | 1.000.000 | 2,60% | Hisse senetleri |
| MORGAN STANLEY | $65.381.263 | 936.560 | 2,43% | Hisse senetleri |
| STATE STREET CORP | $63.504.691 | 909.679 | 2,36% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $61.536.312 | 881.306 | 2,29% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.502.497 | 823.700 | 2,14% | Alım opsiyonu |
| Prosight Management, LP | $56.546.100 | 810.000 | 2,10% | Hisse senetleri |
| ARMISTICE CAPITAL, LLC | $50.542.440 | 724.000 | 1,88% | Hisse senetleri |
| VANGUARD GROUP INC | $43.425.322 | 1.027.089 | 1,62% | Hisse senetleri |
| GILDER GAGNON HOWE & CO LLC | $41.946.944 | 600.873 | 1,56% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $33.377.557 | 478.120 | 1,24% | Hisse senetleri |
| BRAIDWELL LP | $33.063.203 | 473.617 | 1,23% | Hisse senetleri |
| Sofinnova Investments, Inc. | $32.933.775 | 471.763 | 1,23% | Hisse senetleri |
| Woodline Partners LP | $32.871.784 | 470.875 | 1,22% | Hisse senetleri |
| ORBIMED ADVISORS LLC | $32.485.804 | 465.346 | 1,21% | Hisse senetleri |
| UBS Group AG | $29.906.604 | 428.400 | 1,11% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $27.540.045 | 394.500 | 1,03% | Satım opsiyonu |
| EMERALD ADVISERS, LLC | $27.236.930 | 390.158 | 1,01% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $24.331.577 | 348.540 | 0,91% | Hisse senetleri |
| DAFNA Capital Management LLC | $22.226.108 | 318.380 | 0,83% | Hisse senetleri |
| NORTHERN TRUST CORP | $21.538.548 | 308.531 | 0,80% | Hisse senetleri |
| Deep Track Capital, LP | $20.943.000 | 300.000 | 0,78% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $19.893.826 | 284.971 | 0,74% | Hisse senetleri |
| 22NW, LP | $19.624.638 | 281.115 | 0,73% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.475.384 | 278.977 | 0,72% | Hisse senetleri |
| PRIMECAP MANAGEMENT CO/CA/ | $19.047.658 | 272.850 | 0,71% | Hisse senetleri |
| BARCLAYS PLC | $18.315.491 | 262.362 | 0,68% | Hisse senetleri |
| Nearwater Capital Markets, Ltd | $18.255.315 | 261.500 | 0,68% | Hisse senetleri |
| EMERALD MUTUAL FUND ADVISERS TRUST | $17.842.528 | 255.587 | 0,66% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $17.046.485 | 244.184 | 0,63% | Hisse senetleri |
| Creek Drive Management Group LLC | $16.963.830 | 243.000 | 0,63% | Hisse senetleri |
| SEVEN GRAND MANAGERS, LLC | $16.754.400 | 240.000 | 0,62% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $16.742.602 | 239.831 | 0,62% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $16.724.731 | 239.575 | 0,62% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $15.950.887 | 228.490 | 0,59% | Hisse senetleri |
| NORGES BANK | $15.030.093 | 215.300 | 0,56% | Hisse senetleri |
| Bronte Capital Management Pty Ltd. | $13.852.678 | 198.434 | 0,52% | Hisse senetleri |
| TWO SIGMA ADVISERS, LP | $13.039.744 | 308.414 | 0,49% | Hisse senetleri |
| CITADEL ADVISORS LLC | $12.251.655 | 175.500 | 0,46% | Satım opsiyonu |
| GREAT POINT PARTNERS LLC | $12.216.750 | 175.000 | 0,45% | Hisse senetleri |
| Caption Management, LLC | $11.944.491 | 171.100 | 0,44% | Alım opsiyonu |
| MILLENNIUM MANAGEMENT LLC | $11.867.700 | 170.000 | 0,44% | Alım opsiyonu |
| AMERIPRISE FINANCIAL INC | $11.584.330 | 165.941 | 0,43% | Hisse senetleri |
| CITADEL ADVISORS LLC | $11.434.878 | 163.800 | 0,43% | Alım opsiyonu |
| CITADEL ADVISORS LLC | $11.151.938 | 159.747 | 0,42% | Hisse senetleri |
Aktivistler ve %5+ sahipler 1 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Nektar Therapeutics ( | 22 Ağustos 2005 | · | İlk başvuru | M&A / satış | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 40 içeriden öğrenenler · 20 yöneticiler · 18 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Howard W Robin | President & CEO | 18 Ağustos 2026 S | 54.627 | 0 | 8 | $-1.424.905 |
| Jillian B. Thomsen | Chief Financial Officer | 16 Şubat 2023 S | 313.497 | 0 | 0 | $0 |
| Gil M Labrucherie | SVP, COO & CFO | 16 Mayıs 2022 S | 312.905 | 0 | 0 | $0 |
| Timothy Harkness | SVP & Chief Financial Officer | 23 Ağustos 2007 A | · | 0 | 0 | $0 |
| Louis Drapeau | Sr. VP Finance, CFO | 14 Mayıs 2007 A | 6.000 | 0 | 0 | $0 |
| Milton J Harris | President of Nektar AL | 04 Mart 2004 S | 743.904 | 0 | 0 | $0 |
| John Nicholson | SVP & Chief Operating Officer | 16 Ağustos 2019 S | 162.759 | 0 | 0 | $0 |
| Bharat M Chowrira | Chief Operating Officer | 01 Şubat 2010 A | · | 0 | 0 | $0 |
| Jonathan Zalevsky | Chief R&D Officer | 18 Ağustos 2026 S | 9.570 | 0 | 7 | $-974.184 |
| Mark Andrew Wilson | Chief Legal Officer | 21 Kasım 2025 A | 21.585 | 0 | 1 | $-34.196 |
| John Northcott | SVP & Chief Commercial Officer | 16 Mayıs 2022 S | 223.210 | 0 | 0 | $0 |
| Stephen K Doberstein | SVP & Chief Scientific Officer | 05 Eylül 2019 P | 107.668 | 0 | 0 | $0 |
| Maninder Hora | SVP Pharma Dev & Mfg Ops | 16 Mayıs 2019 S | 94.694 | 0 | 0 | $0 |
| Ivan P. Gergel | SVP & Chief Medical Officer | 15 Kasım 2017 A | 56.553 | 0 | 0 | $0 |
| Robert Medve | SVP & Chief Medical Officer | 05 Şubat 2014 A | · | 0 | 0 | $0 |
| Rinko Ghosh | Chief Business Officer | 06 Şubat 2013 A | 9.753 | 0 | 0 | $0 |
| Randall W Moreadith | SVP Drug Development | 23 Şubat 2009 A | · | 0 | 0 | $0 |
| John Stuart Patton | Chief Scientific Officer | 14 Kasım 2008 M | 313.880 | 0 | 0 | $0 |
| Nevan C Elam | SVP & Head of Pulmonary Bus | 25 Şubat 2008 A | 1.400 | 0 | 0 | $0 |
| David Johnston | SVP, Research & Development | 14 Mayıs 2007 D | 6.600 | 0 | 0 | $0 |
| Diana Brainard | Yönetim kurulu üyesi | 23 Eylül 2026 A | 3.904 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | Yönetim kurulu üyesi | 23 Eylül 2026 A | 4.277 | 0 | 0 | $0 |
| Robert Chess | Yönetim kurulu üyesi | 23 Eylül 2026 A | 19.019 | 0 | 0 | $0 |
| Scott R Greer | Yönetim kurulu üyesi | 23 Eylül 2026 A | 22.239 | 0 | 0 | $0 |
| Roy A Whitfield | Yönetim kurulu üyesi | 23 Eylül 2026 A | 16.417 | 0 | 0 | $0 |
| Myriam Curet | Yönetim kurulu üyesi | 19 Eylül 2023 A | 27.418 | 0 | 0 | $0 |
| Karin Eastham | Yönetim kurulu üyesi | 16 Eylül 2022 A | 23.233 | 0 | 0 | $0 |
| Lutz Lingnau | Yönetim kurulu üyesi | 22 Eylül 2020 A | 35.800 | 0 | 0 | $0 |
| Christopher A Kuebler | Yönetim kurulu üyesi | 27 Eylül 2018 A | 45.250 | 0 | 0 | $0 |
| Dennis L Winger | Yönetim kurulu üyesi | 21 Ağustos 2018 M | 42.750 | 0 | 0 | $0 |
| Joseph J Krivulka | Yönetim kurulu üyesi | 19 Eylül 2017 A | 82.000 | 0 | 0 | $0 |
| Susan Wang | Yönetim kurulu üyesi | 20 Kasım 2015 M | 20.000 | 0 | 0 | $0 |
| BROWN MICHAEL A/CA | Yönetim kurulu üyesi | 15 Eylül 2009 A | 10.000 | 0 | 0 | $0 |
| Hoyoung Huh | Yönetim kurulu üyesi | 02 Aralık 2008 A | · | 0 | 0 | $0 |
| Irwin Lerner | Yönetim kurulu üyesi | 02 Aralık 2008 A | 10.000 | 0 | 0 | $0 |
| James B Glavin | Yönetim kurulu üyesi | 04 Eylül 2003 A | · | 0 | 0 | $0 |
| Masuoka K. Lorianne | · | 08 Şubat 2011 A | · | 0 | 0 | $0 |
| Ajit Gill | President & CEO | 23 Mart 2006 S | 87.991 | 0 | 0 | $0 |
| Ajay Bansal | · | 10 Mart 2006 S | 5.166 | 0 | 0 | $0 |
| Melvin Perelman | · | 02 Eylül 2004 A | · | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 26 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| SPIT · RBB Fund, Inc. | 2,05% | 9.695 NS | 31 Temmuz 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,42% | 4.138 NS | 31 Temmuz 2026 | N-PORT |
| BBC · ETFis Series Trust I | 0,80% | 5.234 NS | 31 Temmuz 2026 | N-PORT |
| DWAS · Invesco Exchange-Traded Fund Trust … | 0,62% | 53.474 SH | 02 Ekim 2026 | Günlük |
| IHE · iShares Trust | 0,55% | 125.055 SH | 11 Eylül 2026 | Günlük |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,34% | 1.670 SH | 02 Ekim 2026 | Günlük |
| IWO · iShares Trust | 0,14% | 289.334 SH | 11 Eylül 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,13% | 33.135 SH | 19 Ağustos 2026 | Günlük |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,08% | 7.900 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,08% | 879.755 SH | 11 Eylül 2026 | Günlük |
| RSSL · Global X Funds | 0,08% | 16.502 NS | 31 Temmuz 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,07% | 198.365 SH | 19 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,07% | 36.763 SH | 02 Ekim 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,03% | 14.592 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,03% | 387.471 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,03% | 92.340 SH | 19 Ağustos 2026 | Günlük |
| WSML · iShares Trust | 0,02% | 1.906 SH | 11 Eylül 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 3.096 SH | 19 Ağustos 2026 | Günlük |
| ITOT · iShares Trust | 0,00% | 48.120 SH | 11 Eylül 2026 | Günlük |
| IWV · iShares Trust | 0,00% | 9.239 SH | 11 Eylül 2026 | Günlük |
| TILT · FlexShares Trust | 0,00% | 810 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.075.430 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.837 SH | 19 Ağustos 2026 | Günlük |
| IWN · iShares Trust | · | 32.591 SH | 11 Eylül 2026 | Günlük |
| ISCB · iShares Trust | · | 1.294 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 6.414 SH | 11 Eylül 2026 | Günlük |
NKTR Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 18 analist
AL
Medyan hedef
$150.50
+245,3%
7 38,9%
Güçlü Al
8 44,4%
Al
3 16,7%
Tut
0 0,0%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
10 analist · 2026-10-04Ortalama hedef $141.40 +224,5%
← Tüm hedeflerin altında
Mevcut fiyat $43.58
Düşük$50.00
Ortalama$141.40
Yüksek$192.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| NKTR | $862M | -4.3 | -43.9% | -297.1% | -500.1% | · |
| ANIP | $1.78B | 23.8 | 43.8% | 8.9% | 16.6% | · |
| ETON | $457M | · | 104.9% | -5.8% | -18.4% | 53.5% |
| RAPP | $1.45B | -10.6 | · | · | -29.8% | · |
| OCUL | $2.62B | -8.5 | -18.5% | -511.9% | -55.4% | · |
| PAHC | · | 12.9 | 17.1% | 6.6% | 29.7% | 33.8% |
| INVA | · | 6.1 | 14.7% | · | · | · |
| MAZE | $2.04B | -13.6 | · | · | -598.9% | · |
| XERS | $1.30B | · | 43.7% | 0.19% | -19.7% | · |
| KARD | · | · | · | · | · | · |
| OMER | $1.23B | -343.6 | · | · | 1.9% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 14, 2026